These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25669913)

  • 1. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.
    Bauer M; Karch R; Zeitlinger M; Philippe C; Römermann K; Stanek J; Maier-Salamon A; Wadsak W; Jäger W; Hacker M; Müller M; Langer O
    J Cereb Blood Flow Metab; 2015 May; 35(5):743-6. PubMed ID: 25669913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[
    Bauer M; Wulkersdorfer B; Karch R; Philippe C; Jäger W; Stanek J; Wadsak W; Hacker M; Zeitlinger M; Langer O
    Br J Clin Pharmacol; 2017 Sep; 83(9):1991-1999. PubMed ID: 28401570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
    Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
    J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data.
    Bauer M; Zeitlinger M; Karch R; Matzneller P; Stanek J; Jäger W; Böhmdorfer M; Wadsak W; Mitterhauser M; Bankstahl JP; Löscher W; Koepp M; Kuntner C; Müller M; Langer O
    Clin Pharmacol Ther; 2012 Feb; 91(2):227-33. PubMed ID: 22166851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cerebral P-glycoprotein expression and function with PET by combined [11C]inhibitor and [11C]substrate scans in rats.
    Müllauer J; Karch R; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Mairinger S; Müller M; Löscher W; Langer O; Kuntner C
    Nucl Med Biol; 2013 Aug; 40(6):755-63. PubMed ID: 23774004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of P-glycoprotein function at the human blood-brain barrier using [
    Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative small-animal PET evaluation of [11C]tariquidar, [11C]elacridar and (R)-[11C]verapamil for detection of P-glycoprotein-expressing murine breast cancer.
    Wanek T; Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Sauberer M; Mairinger S; Strommer S; Wacheck V; Löscher W; Erker T; Müller M; Langer O
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):149-59. PubMed ID: 21983837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.
    Mairinger S; Bankstahl JP; Kuntner C; Römermann K; Bankstahl M; Wanek T; Stanek J; Löscher W; Müller M; Erker T; Langer O
    Epilepsy Res; 2012 Jun; 100(1-2):93-103. PubMed ID: 22342565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of HM30181 with P-glycoprotein at the murine blood-brain barrier assessed with positron emission tomography.
    Bauer F; Wanek T; Mairinger S; Stanek J; Sauberer M; Kuntner C; Parveen Z; Chiba P; Müller M; Langer O; Erker T
    Eur J Pharmacol; 2012 Dec; 696(1-3):18-27. PubMed ID: 23022332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
    Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
    J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.
    Wanek T; Mairinger S; Langer O
    J Labelled Comp Radiopharm; 2013; 56(3-4):68-77. PubMed ID: 24285312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.